Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21ClN2O4.ClH |
Molecular Weight | 425.306 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ClC1=CC=C(OCC(=O)N2CCN(CC3=CC4=C(OCO4)C=C3)CC2)C=C1
InChI
InChIKey=MVOWQBJZZKOQNU-UHFFFAOYSA-N
InChI=1S/C20H21ClN2O4.ClH/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18;/h1-6,11H,7-10,12-14H2;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H21ClN2O4 |
Molecular Weight | 388.845 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of methyl mercury, mercuric sulfide and cinnabar on active avoidance responses, Na+/K+-ATPase activities and tissue mercury contents in rats. | 2001 Apr |
|
Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. | 2004 May 25 |
|
Metabolomics in drug intolerance. | 2009 Nov |
|
Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. | 2010 May 15 |
|
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. | 2012 Oct |
|
Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. | 2013 Jun 17 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3519097
Geriatric patients received 600 mg fipexide daily for a period of 3 weeks. Treatment with fipexide was associated with a significant improvement in each and all monitored symptoms and signs to an average extent of 60%, relative to placebo. Overall, 85% of the patients given fipexide experienced clinical improvement to a greater or lesser degree.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18022964
Rat and human hepatocytes were incubated with 20 and 100 microM fipexide for 0, 2 and 6 hours at 30 deg-C. Samples were then quenched with equal volumes of ice-cold acetonitrile and centrifuged at 12000 rpm for 10 min at 4 deg-C. The supernatant was diluted 1:1 with water prior to injection into LC/MS to test whether the catechol metabolite or fipexide could be profiled for protein binding.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:22:49 UTC 2023
by
admin
on
Fri Dec 15 18:22:49 UTC 2023
|
Record UNII |
NQ702L425I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
251-856-9
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
SUB02193MIG
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
34161-23-4
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
DTXSID6047446
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
NQ702L425I
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
161803
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
100000086969
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | |||
|
m5385
Created by
admin on Fri Dec 15 18:22:49 UTC 2023 , Edited by admin on Fri Dec 15 18:22:49 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |